直接口服抗凝药在终末期肾病与肾移植患者中的应用
综述探讨阿哌沙班与利伐沙班在终末期肾病(ESRD)及肾移植人群中的使用。两者均经肾排泄,肾功能不全或透析时暴露增加;现有数据提示阿哌沙班预防血栓栓塞至少与华法林相当且出血风险可能更低,利伐沙班数据有限且不一致。两者已用于肾移植等待期及移植后患者。
要点
- 阿哌沙班在ESRD患者中预防血栓栓塞至少与华法林相当,出血风险可能更低。
- 利伐沙班在ESRD人群的数据有限且结果不一致,需谨慎使用。
- 阿哌沙班和利伐沙班均已用于肾移植等待期及移植后抗凝。
核心结论
- 现有临床试验与真实世界数据提示阿哌沙班在ESRD患者中预防血栓栓塞至少与华法林相当,出血风险可能更低。
- 利伐沙班在ESRD人群的数据更有限且报告结果更不一致。
- 阿哌沙班和利伐沙班均已成功用于ESRD肾移植等待期及移植后患者。
研究设计与样本
- 综述汇总现有临床试验与真实世界数据,评估阿哌沙班和利伐沙班在ESRD及肾移植患者中的应用。
主要发现
- 阿哌沙班和利伐沙班均经一定程度的肾排泄,肾功能不全和/或接受肾脏替代治疗(RRT)者总药物暴露增加。
- 阿哌沙班在ESRD患者中预防血栓栓塞至少与华法林相当,出血风险可能更低。
- 利伐沙班在ESRD人群的数据更有限,报告结果更不一致。
- 阿哌沙班和利伐沙班均已成功用于ESRD肾移植等待期及移植后患者。
临床怎么用
- 在ESRD患者中选用阿哌沙班抗凝时,现有数据支持其血栓栓塞预防效果至少与华法林相当且出血风险可能更低。
- 利伐沙班用于ESRD患者需谨慎,因数据有限且结果不一致。
- 肾移植等待期及移植后患者可考虑使用阿哌沙班或利伐沙班,但需个体化评估。
- 需前瞻性临床试验纳入ESRD及肾移植受者,以明确阿哌沙班和利伐沙班在复杂人群中的角色。
局限性
- 利伐沙班在ESRD人群的现有数据有限且结果不一致。
- 需前瞻性临床试验进一步评估阿哌沙班和利伐沙班在ESRD及肾移植患者中的安全性与有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Direct oral anticoagulant (DOAC) use has significantly increased because major medical organizations endorse their role for conditions in which anticoagulation is indicated. Owing to important pharmacokinetic properties, the use of apixaban and rivaroxaban requires careful consideration in at-risk populations such as those with kidney disease. Both apixaban and rivaroxaban undergo some degree of renal elimination, and thus total drug exposure is increased in patients with renal insufficiency and/or those undergoing renal replacement therapy (RRT). The available clinical trial and real-world data in this population suggests that apixaban is likely at least comparably effective as warfarin at preventing thromboembolic events and is likely safer when evaluating bleeding risk. Rivaroxaban data is more limited, and the reported results are more discordant. Both apixaban and rivaroxaban have been used successfully in patients with end-stage renal disease (ESRD) undergoing kidney transplant listing as well as in the posttransplant setting. Prospective clinical trials evaluating the safety and efficacy of apixaban and rivaroxaban in various conditions where anticoagulation is indicated should include patients with ESRD and kidney transplant recipients to help further define the role that these important novel agents should play in these complex patient populations.
引用
- Lange NW, Muir J, Salerno DM, et al. Direct Oral Anticoagulants in Patients With ESRD and Kidney Transplantation. Kidney Int Rep. 2024. PMID: 39810765. doi:10.1016/j.ekir.2024.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。